Stocksigma LogoStocksigma Logo

Fredun Pharmaceuticals Approves NSE Listing Application Alongside Strong Q2 Earnings

Fredun Pharmaceuticals' Board approved applying for listing on the NSE on 5th Nov'26. For Q2 ended 30th Sep'26, consolidated total income surged 84.19% YoY

Fredun Pharmaceuticals Approves NSE Listing Application Alongside Strong Q2 Earnings

Fredun Pharmaceuticals Ltd · Others (Uncategorized) · 05 Nov 2026, 5:11 pm

Fredun Pharmaceuticals Approves NSE Listing Application Alongside Strong Q2 Earnings Fredun Pharmaceuticals' Board approved applying for listing on the NSE on 5th Nov'26. For Q2 ended 30th Sep'26, consolidated total income surged 84.19% YoY to ₹26,763.50 lakhs from ₹14,529.15 lakhs, while consolidated net profit jumped 96.93% YoY to ₹1,857.42 lakhs versus ₹943.17 lakhs in Q2 ended 30th Sep'25. Standalone net profit reached ₹1,882.57 lakhs with basic EPS of ₹11.21. For H1 ended 30th Sep'26, consolidated net profit rose 95.75% YoY to ₹3,170.65 lakhs. Statutory auditors issued unmodified limited review reports.

Original exchange filing (PDF)

More announcements from Fredun Pharmaceuticals Ltd

All Fredun Pharmaceuticals Ltd announcements